# AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

> **NCT00463814** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 58 (actual)

## Conditions studied

- Tumor
- Cancer

## Interventions

- **DRUG:** AZD6244

## Key facts

- **NCT ID:** NCT00463814
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2007-03-08
- **Primary completion:** 2008-06-17
- **Final completion:** 2025-12-31
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00463814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00463814, "AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00463814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*